- Home
- LAUR vs XENE Comparison
LAUR vs XENE Comparison
Compare LAUR & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAUR
- XENE
- Stock Information
- Founded
- LAUR 1989
- XENE 1996
- Country
- LAUR United States
- XENE Canada
- Employees
- LAUR N/A
- XENE N/A
- Industry
- LAUR Other Consumer Services
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- LAUR Real Estate
- XENE Health Care
- Exchange
- LAUR Nasdaq
- XENE Nasdaq
- Market Cap
- LAUR 2.9B
- XENE 2.5B
- IPO Year
- LAUR 2017
- XENE 2014
- Fundamental
- Price
- LAUR $22.88
- XENE $35.07
- Analyst Decision
- LAUR Buy
- XENE Strong Buy
- Analyst Count
- LAUR 2
- XENE 9
- Target Price
- LAUR $20.50
- XENE $56.22
- AVG Volume (30 Days)
- LAUR 799.3K
- XENE 853.6K
- Earning Date
- LAUR 05-01-2025
- XENE 05-12-2025
- Dividend Yield
- LAUR N/A
- XENE N/A
- EPS Growth
- LAUR 143.51
- XENE N/A
- EPS
- LAUR 1.90
- XENE N/A
- Revenue
- LAUR $1,527,432,000.00
- XENE N/A
- Revenue This Year
- LAUR $2.07
- XENE N/A
- Revenue Next Year
- LAUR $6.82
- XENE $1,553.36
- P/E Ratio
- LAUR $12.09
- XENE N/A
- Revenue Growth
- LAUR 1.26
- XENE N/A
- 52 Week Low
- LAUR $13.60
- XENE $26.74
- 52 Week High
- LAUR $23.05
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- LAUR 73.62
- XENE 50.20
- Support Level
- LAUR $19.71
- XENE $34.47
- Resistance Level
- LAUR $23.06
- XENE $36.44
- Average True Range (ATR)
- LAUR 0.62
- XENE 1.44
- MACD
- LAUR 0.34
- XENE -0.19
- Stochastic Oscillator
- LAUR 95.92
- XENE 28.63
About LAUR Laureate Education Inc.
Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions. Its geographical segments include Peru and Mexico.
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.